CA Patent

CA2967664C — Pharmaceutical formulations comprising inhibitors of human histone methyltransferase ezh2

Assigned to Eisai R&D Management Co Ltd · Expires 2025-12-09 · 0y expired

What this patent protects

The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CA2967664C
Jurisdiction: CA
Classification: —
Expires: 2025-12-09
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.